The investment bank believes there's more risk for a downside on the company's stock than there is potential for an upside.
The investment bank said the company's stock has performed well in recent years and is now "appropriately priced."
The investment bank also raised its outlook on the life science tools sector, lowered its view of labs, and stayed steady on diagnostics.
Wells Fargo downgraded Cepheid from Outperform to Market Perform, citing the firm's "credibility and visibility" following a revised 2017 outlook.
GenMark officials announced an expected delay in launching the CE-marked version of the ePlex system, which in turn affected its US launch timeline.
The investment bank issued its downgrade citing concerns about changes to Cepheid's sales force and a flattening of its MRSA assay sales.
In addition to a steep slide in the company's share price, Raymond James lowered its rating for Cepheid's stock to Market Perform.
BTIG and Mizuho downgraded Illumina's stock after it preannounced third quarter revenue estimates that fell short of analysts' average expectations.
The investment bank also cited challenges for Illumina in penetrating the clinical diagnostics markets and driving physician adoption of its tests.
The investment bank downgraded Illumina to a Neutral rating after the company missed the consensus Wall Street estimate for its revenues.
Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.
New Scientist reports that 20 percent of human and yeast proteins are uncharacterized.
The University of Zurich's Ruedi Aebersold and his colleagues analyzed a dozen HeLa cell lines to find differences in gene expression, protein levels, and more.
In Nature this week: protein-coding variants associated with body-fat distribution, and more.